The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...

The European Medicines Agency (EMA) said on Monday it would no longer post on X and would use rival Bluesky instead, becoming ...

Last month, the European Medicines Agency allowed Novo to add risk reduction for events related to kidney disease to the ...

Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th ...

EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced ...

The European Medicines Agency (EMA), which is the regulator for vaccines and medicine in the European Union (EU), has stopped ...

Novo Nordisk said the Food and Drug Administration approved the diabetes-drug Ozempic to be used to help kidney-disease patients. Ozempic, or semaglutide, can now be used to reduce the risk of ...

In a report released yesterday, Kostas Biliouris from BMO Capital maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency (EMA) has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix (GSK’s Recombinant ...

The European Medicines Agency (EMA) has decided to stop using the social media platform X due to content concerns and will instead use Bluesky. This move aligns with other organizations stepping back ...

GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.29 billion and currently ...

Biogen and Eisai have won Food and Drug Administration approval of an intravenous maintenance dosing of their Leqembi drug for early Alzheimer's disease. The companies late Sunday said the FDA ...